論文 - 手塚　俊樹

【Neuro-COVID-19】COVID-19の神経障害　頭痛・筋痛

滝沢, 翼, 手塚, 俊樹 and 鈴木, 則宏

Clinical Neuroscience 39 （ 3 ） 327 - 330 2021年03月

ISSN  0289-0585

【COVID-19と神経治療学】COVID-19に合併する神経症候

手塚, 俊樹 and 中原, 仁

神経治療学 38 （ 1 ） 7 - 13 2021年01月

ISSN  0916-8443

Evaluation of [(18)F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies

Tezuka, T., Takahata, K., Seki, M., Tabuchi, H., Momota, Y., Shiraiwa, M., Suzuki, N., Morimoto, A., Nakahara, T., Iwabuchi, Y., Miura, E., Yamamoto, Y., Sano, Y., Funaki, K., Yamagata, B., Ueda, R., Yoshizaki, T., Mashima, K., Shibata, M., Oyama, M., Okada, K., Kubota, M., Okita, H., Takao, M., Jinzaki, M., Nakahara, J., Mimura, M. and Ito, D.

Brain Commun 3 （ 4 ） fcab190 2021年

ISSN  2632-1297

　概要を見る

Tau aggregates represent a key pathologic feature of Alzheimer's disease and other neurodegenerative diseases. Recently, PET probes have been developed for in vivo detection of tau accumulation; however, they are limited because of off-target binding and a reduced ability to detect tau in non-Alzheimer's disease tauopathies. The novel tau PET tracer, [(18)F]PI-2620, has a high binding affinity and specificity for aggregated tau; therefore, it was hypothesized to have desirable properties for the visualization of tau accumulation in Alzheimer's disease and non-Alzheimer's disease tauopathies. To assess the ability of [(18)F]PI-2620 to detect regional tau burden in non-Alzheimer's disease tauopathies compared with Alzheimer's disease, patients with progressive supranuclear palsy (n = 3), corticobasal syndrome (n = 2), corticobasal degeneration (n = 1) or Alzheimer's disease (n = 8), and healthy controls (n = 7) were recruited. All participants underwent MRI, amyloid β assessment and [(18)F]PI-2620 PET (Image acquisition at 60-90 min post-injection). Cortical and subcortical tau accumulations were assessed by calculating standardized uptake value ratios using [(18)F]PI-2620 PET. For pathologic validation, tau pathology was assessed using tau immunohistochemistry and compared with [(18)F]PI-2620 retention in an autopsied case of corticobasal degeneration. In Alzheimer's disease, focal retention of [(18)F]PI-2620 was evident in the temporal and parietal lobes, precuneus, and cingulate cortex. Standardized uptake value ratio analyses revealed that patients with non-Alzheimer's disease tauopathies had elevated [(18)F]PI-2620 uptake only in the globus pallidus, as compared to patients with Alzheimer's disease, but not healthy controls. A head-to-head comparison of [(18)F]PI-2620 and [(18)F]PM-PBB3, another tau PET probe for possibly visualizing the four-repeat tau pathogenesis in non-Alzheimer's disease, revealed different retention patterns in one subject with progressive supranuclear palsy. Imaging-pathology correlation analysis of the autopsied patient with corticobasal degeneration revealed no significant correlation between [(18)F]PI-2620 retention in vivo. High [(18)F]PI-2620 uptake at 60-90 min post-injection in the globus pallidus may be a sign of neurodegeneration in four-repeat tauopathy, but not necessarily practical for diagnosis of non-Alzheimer's disease tauopathies. Collectively, this tracer is a promising tool to detect Alzheimer's disease-tau aggregation. However, late acquisition PET images of [(18)F]PI-2620 may have limited utility for reliable detection of four-repeat tauopathy because of lack of correlation between post-mortem tau pathology and different retention pattern than the non-Alzheimer's disease-detectable tau radiotracer, [(18)F]PM-PBB3. A recent study reported that [(18)F]PI-2620 tracer kinetics curves in four-repeat tauopathies peak earlier (within 30 min) than Alzheimer's disease; therefore, further studies are needed to determine appropriate PET acquisition times that depend on the respective interest regions and diseases.

• Access to Document (DOI)

磁化率強調画像におけるswallow tail signのパーキンソン病診断における有用性

関, 守信, 上田, 亮, 手塚, 俊樹, 馬島, 恭子, 吉崎, 崇仁 and 中原, 仁

臨床神経学 60 （ Suppl. ） S407 2020年11月

ISSN  0009-918X

網膜片頭痛様の症状を呈したEvans症候群の1例

手塚, 俊樹, 柴田, 護, 伊澤, 良兼, 菊池, 拓, 藤原, 広和, 秋野, 邦彦, 小沢, 洋子, 中原, 仁 and 滝沢, 翼

日本頭痛学会誌 47 （ 2 ） O2 - 2 2020年11月

ISSN  1345-6547

髄液中の抗原、PCR検査で診断に至ったアスペルギルス髄膜炎の1例

寺山, 千夏, 勝又, 雅裕, 関口, 耕史, 手塚, 俊樹, 伊達, 悠岳, 阿部, 雅広 and 中原, 仁

日本内科学会関東地方会 662回   57 2020年09月

Novel tau tracer, PI 2620, for Alzheimer's disease(AD) and non-AD tauopathies

手塚, 俊樹, 高畑, 圭輔, 関, 守信, 田渕, 肇, 上田, 亮, 馬島, 恭子, 大山, 宗徳, 岡田, 健祐, 船木, 桂, 山縣, 文, 吉崎, 崇仁, 中原, 理紀, 百田, 友紀, 白岩, 美花, 柴田, 護, 三浦, 瑛祐, 陣崎, 雅弘, 中原, 仁, 三村, 將 and 伊東, 大介

Dementia Japan 33 （ 4 ） 513 2019年10月

ISSN  1342-646X

磁化率強調画像におけるswallow tail signのパーキンソン病及び関連疾患診断における有用性

関, 守信, 上田, 亮, 手塚, 俊樹, 岡田, 健佑, 馬島, 恭子, 吉崎, 崇仁 and 中原, 仁

神経治療学 36 （ 6 ） S262 2019年10月

ISSN  0916-8443

【認知症早期診断・発症進行予防とリハビリテーション】認知症・神経変性疾患診療における次世代タウPETプローブの可能性　プロティノパチーイメージングの時代を迎えて

伊東, 大介 and 手塚, 俊樹

MEDICAL REHABILITATION  （ 241 ） 18 - 21 2019年10月

ISSN  1346-0773

　概要を見る

近年の病理学、分子遺伝学の発展により、ほとんどの神経変性疾患は、特定の蛋白質が障害部位に異常蓄積するプロティノパチーとして理解されるようになった。異常蛋白質の蓄積は、病態メカニズムの理解だけでなく診断、治療においても重要なターゲットとなっている。それまで構造画像と機能画像に頼られていた神経変性疾患のイメージング技術は、2004年にピッツバーグ大学のKlunkらにより報告されたアミロイドイメージングによりプロティノパチーイメージングの時代となった。さらに、Maruyamaらの報告を皮切りに、我が国を含めた技術開発によりタウ病変の画像化も可能となり、多種にわたるタウオパチーの精度の高い診断、鑑別が可能となりつつある。本稿では、タウオパチー診療におけるタウPETプローブの現状と可能性について論ずる。(著者抄録)

パーキンソン病患者におけるパレイドリアは認知症の指標になる可能性がある

馬島, 恭子, 長田, 高志, 吉崎, 崇仁, 渡邊, 由里香, 野口, 恵理, 谷川, 万里子, 大山, 宗徳, 手塚, 俊樹, 岡田, 健佑, 中原, 仁 and 関, 守信

パーキンソン病・運動障害疾患コングレスプログラム・抄録集 13回   121 2019年07月

パーキンソン病患者における睡眠障害と覚醒障害の包括的検討

関, 守信, 長田, 高志, 吉崎, 崇仁, 谷川, 万里子, 野口, 恵理, 馬島, 恭子, 大山, 宗徳, 岡田, 健佑, 手塚, 俊樹 and 中原, 仁

パーキンソン病・運動障害疾患コングレスプログラム・抄録集 13回   121 2019年07月

Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines

Fujimori, K., Tezuka, T., Ishiura, H., Mitsui, J., Doi, K., Yoshimura, J., Tada, H., Matsumoto, T., Isoda, M., Hashimoto, R., Hattori, N., Takahashi, T., Morishita, S., Tsuji, S., Akamatsu, W. and Okano, H.

Mol Brain 9 （ 1 ） 88 2016年10月

ISSN  1756-6606

　概要を見る

Patient-specific induced pluripotent stem cells (iPSCs) facilitate understanding of the etiology of diseases, discovery of new drugs and development of novel therapeutic interventions. A frequently used starting source of cells for generating iPSCs has been dermal fibroblasts (DFs) isolated from skin biopsies. However, there are also numerous repositories containing lymphoblastoid B-cell lines (LCLs) generated from a variety of patients. To date, this rich bioresource of LCLs has been underused for generating iPSCs, and its use would greatly expand the range of targeted diseases that could be studied by using patient-specific iPSCs. However, it remains unclear whether patient's LCL-derived iPSCs (LiPSCs) can function as a disease model. Therefore, we generated Parkinson's disease patient-specific LiPSCs and evaluated their utility as tools for modeling neurological diseases. We established iPSCs from two LCL clones, which were derived from a healthy donor and a patient carrying PARK2 mutations, by using existing non-integrating episomal protocols. Whole genome sequencing (WGS) and comparative genomic hybridization (CGH) analyses showed that the appearance of somatic variations in the genomes of the iPSCs did not vary substantially according to the original cell types (LCLs, T-cells and fibroblasts). Furthermore, LiPSCs could be differentiated into functional neurons by using the direct neurosphere conversion method (dNS method), and they showed several Parkinson's disease phenotypes that were similar to those of DF-iPSCs. These data indicate that the global LCL repositories can be used as a resource for generating iPSCs and disease models. Thus, LCLs are the powerful tools for generating iPSCs and modeling neurological diseases.

• Access to Document (DOI)

糖尿病性下肢壊疽を来たし、腸腰筋膿瘍から敗血症性ショックを来した1例

手塚, 俊樹, 細谷, 幸司, 安田, 聖一, 日比野, 祐香, 小松, 素明, 加藤, 優子 and 竜崎, 崇和

日本透析医学会雑誌 49 （ Suppl.1 ） 440 2016年05月

ISSN  1340-3451